Clinical Trial Results:
A multicentre, open label, phase IIb clinical trial to evaluate safety, tolerability and efficacy of the depigmented modified allergen extract of two mites mixes at 200 DPP/ml (DP/MG/14-1 Dermatophagoides pteronyssinus / Lepidoglyphus destructor and DP/MG/14-2 Dermatophagoides pteronyssinus /Blomia tropicalis) in subjects with allergic rhinitis or rhinoconjunctivitis, with controlled allergic asthma.
Summary
|
|
EudraCT number |
2014-000172-26 |
Trial protocol |
ES |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1 |
This version publication date |
12 Sep 2021
|
First version publication date |
12 Sep 2021
|
Other versions |
v2 |
Summary report(s) |
Prematurely end |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.